Talking to patients about biosimilars
| Autor: | Jennifer Coppola, Yelena Y. Janjigian, Giuseppe Curigliano, Mark Latymer, Marco Bissig |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Health Personnel 03 medical and health sciences 0302 clinical medicine Neoplasms medicine Animals Humans Intensive care medicine Treatment costs Biosimilar Pharmaceuticals business.industry Biologic therapies Biosimilar General Medicine United States Europe Treatment Outcome 030104 developmental biology Oncology 030220 oncology & carcinogenesis Patient communication business Healthcare providers |
| Zdroj: | Future Oncology. 14:2403-2414 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2018-0044 |
| Popis: | Biologic therapies target aberrant pathways in diseases including diabetes, cancer and autoimmune disorders. Despite recent scientific advances, patient access to these agents can be limited. Biosimilars are designed to be highly similar to the originator biologic, targeting the same biological pathways, with comparable efficacy and safety. Biosimilars have the advantage of lower treatment costs, offering the potential for increased clinical use and patient access. Several biosimilars are approved for clinical use in the USA and Europe; however, there is a lack of awareness about biosimilars among healthcare providers and patients. This overview of the scientific basis of biosimilars and current indications aim to enhance discussions with patients and increase understanding of the role of biosimilars in individual treatment plans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|